Latest 10-K annual reports

The LGL Group, Inc. reported a 59.3% increase in net income attributable to common stockholders for 2025, primarily driven by a significant income tax benefit, despite a decline in total revenues and operational income.

Pathfinder Bancorp, Inc. reported a net loss of $1.9 million for the full year 2025, primarily driven by a significant increase in provision for credit losses and fair value adjustments on loans held-for-sale.

Pyrophyte Acquisition Corp. II, a blank check company, reported net income of $2.97 million for 2025 while actively searching for an initial business combination in the energy sector.

Camber Energy reported a significantly reduced net loss for 2025, driven by a gain on subsidiary disposal, but continues to face substantial doubt about its ability to continue as a going concern amidst operational challenges and material weaknesses in internal controls.

Glucotrack, Inc. reports progress on its implantable continuous blood glucose monitor and recent financing, but faces substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing challenges.

PDS Biotechnology Corporation's 2025 annual report highlights significant progress in its oncology pipeline with promising clinical trial results for PDS0101 and PDS01ADC, despite ongoing financial losses and a going concern warning.

Nuo Therapeutics, a medical device company, announced significant revenue growth in 2025 driven by its Aurix product and a new distribution agreement with Smith+Nephew, alongside securing new debt financing, despite ongoing net losses and a going concern warning.

StableX Technologies, Inc. has completed its strategic pivot from electric vehicle manufacturing to digital asset treasury management, reporting a significant net loss of $21.09 million for 2025 amidst market volatility and ongoing capital needs.

Interpace Biosciences reports a significant net income increase in 2025 driven by a tax benefit, despite an 18% revenue decline following the discontinuation of its PancraGEN test.

Spark I Acquisition Corp. reports a net income of $293,600 for fiscal year 2025, actively negotiating a binding business combination with AI solutions provider Kneron Holding Corporation amidst a going concern warning and significant redemptions.

Dragonfly Energy Holdings Corp. saw revenue growth in 2025 driven by OEM sales, but reported a significantly increased net loss due to debt extinguishment and ongoing operational costs.

Yale Transaction Finders, a shell company, reported a net loss for fiscal year 2025, continued to rely on related-party financing, and disclosed material weaknesses in internal controls.

TriLinc Global Impact Fund, LLC reported a decrease in its net asset value per unit for the year ended December 31, 2025, alongside ongoing liquidity constraints and a suspension of regular distributions.

Myseum, Inc. reported a net loss of $3.04 million for fiscal year 2025, driven by operating expenses despite a significant gain from the deconsolidation of its RPM Interactive subsidiary.

Lightstone Value Plus REIT IV, Inc. reported its annual results for 2025, showing a reduced net loss and improved hotel performance, despite a slight decline in Net Asset Value per share to $9.38.

CareView Communications, Inc. reported reduced net and operating losses and increased revenue for fiscal year 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Lantern Pharma, an AI-driven oncology firm, reported continued net losses in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing multiple drug candidates and expanding its AI platform.

AEON Biopharma, Inc. reports significant losses and going concern doubt in its 2025 annual filing, while advancing its ABP-450 botulinum toxin biosimilar program with positive analytical study results and strategic financing efforts.

Mesa Royalty Trust's 2025 annual report shows a decrease in royalty income but an increase in distributable income per unit, alongside rising excess production costs and plans to increase cash reserves.

Tivic Health Systems, Inc. completed a strategic transformation in 2025, shifting from bioelectronic devices to a biopharmaceutical focus on its TLR5 agonist program Entolimod, while reporting significant losses and raising substantial doubt about its ability to continue as a going concern.

Legence Corp. announced its 2025 financial results, showcasing significant revenue growth and a substantial increase in backlog, despite reporting a net loss and goodwill impairments.

Boston Omaha Corporation reported a significant reduction in net loss for fiscal year 2025, driven by revenue growth in its core billboard and broadband segments and strategic cost-cutting in asset management.

DiaMedica Therapeutics' 2025 annual report details progress in DM199 clinical trials for preeclampsia and stroke, alongside financial losses and enrollment challenges.

VanEck Avalanche ETF's 2025 annual report details significant asset growth and operational setup, alongside extensive disclosures on the inherent volatility and regulatory challenges of the digital asset market.

Firsthand Technology Value Fund, Inc. reported a significant net loss for 2025, with total liabilities exceeding assets, raising substantial doubt about its ability to continue as a going concern.

Chase Packaging Corporation, a shell company, reported a net loss of $76,742 for fiscal year 2025 and extended the expiration date of its outstanding warrants to March 7, 2029, as it continues to seek a merger or acquisition.

RenovoRx, a life sciences company, reported $1.1 million in RenovoCath sales for 2025 and continued progress in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer.

Quest Patent Research Corporation reported a significant net loss of $8.5 million and no revenue for the year ended December 31, 2025, raising substantial doubt about its ability to continue as a going concern.

CXApp Inc. reported a 36% revenue decline and a $13.473 million net loss for 2025, while facing a Nasdaq delisting notice for its stock price.

Jasper Therapeutics reports positive clinical data for briquilimab in mast cell diseases, but faces significant net losses and substantial doubt about its ability to continue as a going concern.